euro-toxicology-2016_scientifictracks-abstracts

15 / 89

Volume 6, Issue 6(Suppl) J Clin Toxicol 2016
ISSN: 2161-0495, JCT an open access journal
Page 47
Notes:
Euro Toxicology 2016
October 24-26, 2016
conferenceseries.com
Toxicology & Applied Pharmacology
October 24-26, 2016 Rome, Italy
7th Euro-Global Summit on
Vancomycin-induced skin eruptions with susceptibility alleles to SJS/TEN
Liping Yang
Beijing Hospital, Dongcheng, P R China
Background & Objective: The glycopeptide antibiotics, vancomycin and teicoplanin, are the mainstay of therapy for severe
gram-positive organisms such as methicillin-resistant Staphylococcus aureus. We report a case of Stevens–Johnson syndrome
(SJS) induced by sequential therapy with teicoplanin and vancomycin, in a patient with chronic obstructive pulmonary disease
(COPD).
Case Summary: A 74-year-old Han Chinese with 1-year history of COPD was admitted for treatment of infective endocarditis.
After teicoplanin therapy for 12 days, he developed pruritus and maculopapular over his trunk and limbs. His rash spread
rapidly to most parts of the body surface area, 7 days after his anti-infection therapy was switched to vancomycin. This was
stopped, but he developed SJS when teicoplanin was reintroduced. This patient recovered from his drug eruptions when both
teicoplanin and vancomycin were stopped. Pharmacogenetic analyses revealed he was heterozygous with respect to 2 variants
(rs2844682 of MUC21 and rs750332 of BAG6).
What is new & Conclusion: Cross-reactivity between vancomycin and teicoplanin is rare. SJS attributable to sequential
treatment with these 2 antibiotics has not been reported previously. Care should be taken when prescribing vancomycin in
patients with a previous documented skin eruption to teicoplanin, especially in those who carry any susceptibility alleles to
SJS/TEN.
Biography
Liping Yang has completed her PhD from RMIT University in Australia. She is the Vice-Director of Pharmacy Department, Beijing Hospital, a large-scale general
hospital. She has published more than 90 papers in reputed journals and has been serving as an Editorial Board Member of repute. Since 2003, she has served
as a Clinical Pharmacist, Senior Clinical Pharmacist, Associate Professor and Professor for the Pharmacy Department, Beijing Hospital, China. Her major interests
are pharmacogenomics, drug-drug interaction, evidence-based medicine, Chinese medicine and rational drug use in clinical setting.
Liping Yang, J Clin Toxicol 2016, 6:6(Suppl)